Chronic graft-versus-host disease (cGVHD) is an increasingly frequent cause of morbidity and mortality of allogeneic hematopoietic stem cell transplantation. Sclerodermatous cGVHD (Scl- 
Introduction
Graft-versus-host disease (GVHD) is the most common cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (HSCT) Furthermore, donor B cells prolong the survival of pathogenic CD4 + T cells 7 . Clinically, studies have demonstrated the efficacy of B cell-targeting therapy using rituximab for cGVHD 11, 12 .
Collectively, B cells play pathogenic roles in the development of cGVHD through diverse can promote tolerogenic immune responses through IL-10-dependent mechanisms [19] [20] [21] [22] [23] [24] [25] . Contact hypersensitivity, experimental autoimmune encephalomyelitis (EAE), lupus, and inflammatory bowel diseases are augmented in CD19 -/-mice due to the lack of B10 cells 18, 19, 24, 26, 27 . In the current study, we investigated the role of Bregs in Scl-cGVHD using CD19 -/-mice.
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Methods

Mice
BALB/c and B10.D2 mice were purchased from Japan SLC (Shizuoka, Japan). CD19 -/-mice were generated as described 28 and backcrossed onto the BALB/c or B10.D2 background ≥ 12 generations. Mice were housed in a specific pathogen-free barrier facility. The Committee on Animal Experimentation of Kanazawa University Graduate School of Medical Science approved all studies and procedures.
BM transplantation
Male wild-type or CD19 -/-B10.D2 mice and female wild-type or CD19 -/-BALB/c mice (8-to-12-week-old) were used as donors and recipients, respectively. BM was T cell-depleted (TCD) with anti-CD90.2 microbeads (Miltenyi Biotech, Auburn, CA). Splenic T and B cells were isolated with anti-CD90.2 and anti-B220 microbeads (Miltenyi Biotech), respectively. Recipients were irradiated with 800 cGy (MBR-1520R, Hitachi, Tokyo, Japan) and were injected with 10x10 6 TCD-BM, 5x10 6 splenic T cells and 5x10 6 splenic B cells in 0.5 mL of PBS to generate SclcGVHD. Control groups received donor cells from BALB/c (syngeneic BMT) or B10.D2 mice (allogeneic BMT). All studies were approved by the institutional review board.
GVHD skin score
Clinical cGVHD score was previously described 29 : healthy appearance = 0; skin lesions with alopecia equal or less than 1 cm 2 in area = 1; 1 to 2 cm 2 = 2; 2 to 5 cm 2 = 3; 5 to 10 cm 2 = 4; 10 to 15 cm 2 = 5; 15 to 20 cm 2 = 6; more than 20 cm 2 = 7. Additionally, animals were assigned 0.4 points for skin disease (lesions or scaling) on tail, and 0.3 points each for lesions on ears and paws. Minimum score = 0, maximum score = 8. Final scores for dead animals were kept in the data set for the remaining time points.
Histological analysis
The skin and lung were fixed in 10% formalin and embedded in paraffin. Sections (6 μm in thickness) were stained with H&E and Masson's trichrome. Skin histopathology was scored by a dermatopathologist (blinded to experimental groups) on the basis of epidermal interface changes, dermal collagen thickness, mononuclear cell inflammation, subdermal fat loss, and follicular dropout with scores from 0 to 2 for each category (total score, 0-10) 30 . Masson's Trichrome staining was used to detect the collagen fibers and collagen deposition. Collagen deposition was quantified on trichrome stained sections as the ratio of blue-stained area to total stained area using Adobe Photoshop CS4 analysis tools.
Flow cytometry
The following monoclonal antibodies (mAbs) were used: FITC-, PE-, PE-Cy5-, PE-Cy7-, PerCP-Cy5.5-, APC-, APC-PECy7-, or Pacific Blue-conjugated mAbs to mouse Thy1.2 (30-
CD5 (30-H12), and CD21 (7G6) (BioLegend, San Diego, CA), and Ly9.1 (30C7) (BD Biosciences, San Jose, CA). and LIVE/DEAD Fixable Aqua Dead cell (Invitrogen, Grand Island, NY) . was used to detect dead cells.
Splenic and skin single-cell suspensions were stained for 20 min for multicolor immunofluorescence analysis using mAbs at predetermined optimal concentrations on a FACSCanto II (BD Biosciences)
29
. Data were analyzed using FlowJo software (Tree Star, Ashland, OR).
Intracellular cytokine staining
B cells and monocytes/macrophages were stimulated for 5 h with LPS (10 μg/mL, SigmaAldrich), PMA (50 ng/mL; Sigma-Aldrich), ionomycin (500 ng/mL; Sigma-Aldrich), and brefeldin A (3 μM; BioLegend) for detection of cytokine production. T cells were stimulated for 4 h with PMA (50 ng/mL), ionomycin (1 μg/mL), and brefeldin A (3 μM; BioLegend). After
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From cell-surface staining, the cells were washed, fixed, and permeabilized using the Cytofix/Cytoperm Kit (BD Biosciences), followed by staining with anti-IL-10 (JES5-16E3) or anti-IL-6 (MP5-20F3) mAbs (BioLegend), or anti-TNF-α (MP6-XT22), anti-IFN-γ (XMG1.2), anti-IL-17A (TC11-18H10.1), or anti-granzyme B (GB11) mAbs (BioLegend) or anti-IL-13 (eBio13A) mAb (eBioscience, San Jose, CA). Skin single-cell suspensions without stimulation were stained with anti-CD11b mAb, followed by intracellular staining with anti-LAP (latencyassociated peptide) mAb (TW7-16B4, BioLegend).
Cell sorting and adoptive transfer experiments
Wild-type B10.D2 mice were used as B cell donors. Splenic B cells were first enriched using CD19 mAb-coated microbeads (Miltenyi Biotec BioLegend) Abs for 72 h. Proliferation was measured by CFSE dilution. For cytokine analysis, T cell were cocultured as above for 72 h, with PMA (50 ng/ml), ionomycin (1000 ng/ml), and brefeldin A (3 μM) added during the final 4 h of culture, followed by intracellular cytokine staining.
CBA (Cytometric Bead Array)
CD11b
+ cells and T cells were cocultured as described above and with recombinant IL-10 (0.5 ng/ml, BioLegend) or anti-mouse IL-10 receptor (IL-10R) mAb (30 μg/ml, 1B1.3e, BioLegend), follơwing by the adding LPS, PMA, and ionomycin during the final 5 h or PMA and ionomycin during final 4h for CD11b + cell coculture or T cell coculture, respectively. Cytokine concentrations in supernatant were measured by CBA inflammatory kit (BD Biosciences).
Statistics
All data are shown as mean ± standard error of the mean (SEM). The significance of differences between sample means was determined with the Student's t test. Figure 1A) , and the ratio of CD8 + /CD4 + T cells was increased beginning 14 days after BMT in the allogeneic BMT group Augmented GVHD severity and fibrosis scores in CD19 -/-donor-transplanted recipients
As described previously 18, 19 , the numbers of IL-10-producing B cells were markedly decreased in CD19 -/-mice on BALB/c and B10.D2 backgrounds compared with their wild-type counterparts (p<0.01; Figure 2A ).. To investigate whether CD19 deficiency expressionon B cells of recipients or donors has effects on Scl-cGVHD, CD19 -/-BALB/c or CD19 -/-B10.D2 mice were used as recipients or donors, respectively. When compared with the control group, there was no significant difference in skin score ( Figure 2B ), histopathological skin score ( Figure 2C ), or fibrosis areas in the skin and lung ( Figure 2D , E) in the CD19 -/-recipient group. Thus, CD19 expression in recipients did not influence Scl-cGVHD. By contrast, CD19 -/-donor cells significantly promoted Scl-cGVHD as evidenced by an increased average skin score compared with the control group (p<0.01 and p<0.05 on day 21 and 42, respectively, Figure 2F ).
Consistently, histopathological skin scores and fibrosis areas in the skin and lungs in the CD19 Figure 3C and D). The most remarkable difference was observed in B10 cells, as the number of B10 cells in CD19 -/-donor-transplanted mice was significantly lower than in CD19 +/+ donor-transplanted mice ( Figure 3E Figure 4B and C). The frequency of granzyme B-producing CD8 + T cells in total T cells was significantly higher in CD19 -/-donor-transplanted mice when compared with that in CD19 +/+ donor-transplanted mice ( Figure 4D ). Therefore, CD8 + T cells, especially granzyme B-producing cytotoxic CD8 + T cells, were increased in CD19 -/-donor-transplanted mice.
IL-6 plays an important role in the pathogenesis of Scl-cGVHD 29 . We noted elevated expansion of splenic monocytes/macrophages (CD11b + cells) in allogeneic BMT mice ( Figure   1C ). On day 14 after BMT, CD11b + cells produced IL-6 at a higher rate than CD11b -cells in both groups ( Figure 4E ). There was a significantly higher percentage of IL-6-producing CD11b + cells among total splenocytes in CD19 -/-donor-transplanted mice compared with CD19 +/+ donor GVHD mice (p<0.05, Figure 4F ). Furthermore, CD19 +/+ donor-transplanted mice showed significantly reduced percentages of TNF-α and IFN-γ-producing CD4 + T cells 14 days after BMT when compared with CD19 -/-donor-transplanted mice (p<0.01, Figure 4G and H). Figure 4I ) or GVHD-derived monocytes/macrophages alone ( Figure 4I ). The inhibitory effect of LPSstimulated CD19 +/+ B cells on cytokine production by CD11b + cells was reduced by adding anti-IL-10R mAb ( Figure 4J ). Furthermore, IL-10 suppressed IL-6 and TNF-α productions by GVHD CD11b + cells in vitro ( Figure 4J ). Therefore, CD19 expression by donor B cells correlates with reduced IL-6 production by monocytes/macrophages. Figure 5B ).
Activated monocyte/macrophage-secreted TGF-β is a key mediator of fibrosis [37] [38] [39] .
When compared with the CD19 +/+ donor-transplanted group, the percentage and number of skin CD11b + LAP + cells were significantly increased in the CD19 -/-donor-transplanted group ( Figure   5C and D). Therefore, donor CD19 expression may contribute to suppression of TGF-β1-producing monocytes/macrophages in the skin.
Increased cutaneous Th2 cells in the CD19 -/-donor-transplanted group
In Scl-cGVHD cutaneous tissue, there is a mixed Th1/Th2-like cytokine profile with a Th1-like predominance during the early stage and Th2-like profile at the later stage 38 . When compared with syngeneic BMT mice, both IFN-γ-producing CD4 + T cells and IL-13-producing CD4 + T cells were clearly increased in the skin of allogeneic BMT mice (data not shown). Nonetheless, the CD19 -/-donor GVHD group showed a modest, but significant, decrease in the percentage of skin IFN-γ-producing CD4 + T cells 21 days after BMT (p=0.045, Figure 5E ). There was no significant change in the percentage of IL-17A-producing CD4 + T cells in either group ( Figure   5F ). In contrast, the percentage of IL-13-producing CD4 + T cells was significantly increased in the skin of CD19 -/-donor GVHD group 21 days after BMT (p=0.0024, Figure 5G , H). Therefore, CD19 deficiency in donor B cells promoted Th2 cell infiltration and reduced Th1 infiltration in the skin in the later stage of Scl-cGVHD. 
Discussion
We herein demonstrate that Breg reconstitution is critical for the suppression of Scl-cGVHD.
Although the percentage of splenic B cells was low during Scl-cGVHD development ( Figure   1D ), Breg percentages were markedly increased in wild-type donor-transplanted mice ( Figure 1E and F). In contrast, the reconstitution of B10 cells was disturbed in CD19 -/-donor-transplanted mice ( Figure 3 ). Additionally, Scl-cGVHD severity and fibrosis were accelerated in CD19 Figure 6F ). Instead, these regulatory cells were cocultured with T cells there was a significant reduction in IFN-γ ( Figure 6G and H).
While precise mechanisms of B10 cell activation in cGVHD remain unclear, optimal expansion of B10 cells has been considered to require the initial stimulation of TLRs followed by BCR and CD40 engagements 43 . Histopathological scores and the ratio of trichome area/total area in the skin (H) and in the lung (I) were evaluated 42 days after BMT. Representative photographs and microphotographs were taken 42 days after BMT. 4-6 mice per group; *p<0.05; **p<0.01; ***p<0.001. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
